======= UBE2E1 =======
== Gene Information ==
* **Official Symbol**: UBE2E1
* **Official Name**: ubiquitin conjugating enzyme E2 E1
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=7324|7324]]
* **UniProt**: [[https://www.uniprot.org/uniprot/P51965|P51965]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=UBE2E1&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20UBE2E1|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/602916|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: N/A
* **UniProt Summary**: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. Catalyzes the covalent attachment of ISG15 to other proteins. Mediates the selective degradation of short-lived and abnormal proteins. In vitro also catalyzes 'Lys-48'-linked polyubiquitination. {ECO:0000269|PubMed:16428300, ECO:0000269|PubMed:20061386}.
|UQ con|
|ISG15 transferase activity|
|ISG15-protein conjugation|
|histone H2B ubiquitination|
|histone monoubiquitination|
|ubiquitin conjugating enzyme activity|
|histone ubiquitination|
|protein K48-linked ubiquitination|
|protein monoubiquitination|
|anaphase-promoting complex-dependent catabolic process|
|ubiquitin ligase complex|
|ubiquitin-protein transferase activity|
|protein polyubiquitination|
|proteasome-mediated ubiquitin-dependent protein catabolic process|
|proteasomal protein catabolic process|
|histone modification|
|covalent chromatin modification|
|regulation of mitotic cell cycle phase transition|
|regulation of cell cycle phase transition|
|ubiquitin-dependent protein catabolic process|
|modification-dependent protein catabolic process|
|modification-dependent macromolecule catabolic process|
|proteolysis involved in cellular protein catabolic process|
|cellular protein catabolic process|
|regulation of mitotic cell cycle|
|protein catabolic process|
|protein ubiquitination|
|chromatin organization|
|regulation of cell cycle process|
|protein modification by small protein conjugation|
|cellular macromolecule catabolic process|
|protein modification by small protein conjugation or removal|
|macromolecule catabolic process|
|organonitrogen compound catabolic process|
|chromosome organization|
|regulation of cell cycle|
|proteolysis|
|ATP binding|
|organic substance catabolic process|
|cellular catabolic process|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp67|BVD-523 15μM R02 exp67]]|-2.86|
|[[:results:exp346|CoCl2 18μM R07 exp346]]|-2.37|
|[[:results:exp535|Trimetrexate 0.03μM R08 exp535]]|-2.35|
|[[:results:exp440|Aphidicolin 0.4μM R08 exp440]]|-2.33|
|[[:results:exp64|Nocodazole 0.2μM R02 exp64]]|-2.28|
|[[:results:exp292|Menadione 5μM R06 exp292]]|-2.2|
|[[:results:exp354|Diepoxybutane 3μM R07 exp354]]|-2.11|
|[[:results:exp46|HMS-I1 1μM R01 exp46]]|-2.11|
|[[:results:exp500|LY2090314 0.003μM R08 exp500 no dilution day6]]|-2.02|
|[[:results:exp59|UMK57 1μM R01 exp59]]|-2.01|
|[[:results:exp106|UM131593 0.2μM R03 exp106]]|-2|
|[[:results:exp499|LY2090314 0.003μM R08 exp499]]|-1.93|
|[[:results:exp282|Fluvastatin 2.2μM R06 exp282]]|-1.84|
|[[:results:exp107|UMK57 0.6μM R03 exp107]]|-1.79|
|[[:results:exp226|Cerivastatin 0.15μM R05 exp226]]|-1.75|
|[[:results:exp478|Doxorubicin 0.02μM R08 exp478]]|-1.72|
|[[:results:exp30|Rapamycin 10μM R00 exp30]]|1.72|
|[[:results:exp11|CCCP 1μM R00 exp11]]|1.73|
|[[:results:exp452|Azithromycin 100μM R08 exp452]]|1.87|
|[[:results:exp6|Bortezomib 0.005μM R00 exp6]]|2.11|
|[[:results:exp29|Rapamycin 1μM R00 exp29]]|2.18|
|[[:results:exp407|Thapsigargin 0.005μM R07 exp407]]|2.25|
|[[:results:exp35|TRAIL 5ng/ml R00 exp35]]|2.52|
|[[:results:exp36|TRAIL 50ng/ml R00 exp36]]|3.02|
^Gene^Correlation^
|[[:human genes:p:pcgf1|PCGF1]]|0.581|
|[[:human genes:r:ring1|RING1]]|0.565|
|[[:human genes:i:ikzf2|IKZF2]]|0.551|
|[[:human genes:b:bcor|BCOR]]|0.518|
|[[:human genes:p:pou2af1|POU2AF1]]|0.5|
|[[:human genes:c:cdk8|CDK8]]|0.45|
|[[:human genes:n:nufip2|NUFIP2]]|0.43|
|[[:human genes:g:glyr1|GLYR1]]|0.416|
|[[:human genes:a:apex2|APEX2]]|0.408|
|[[:human genes:z:znf217|ZNF217]]|0.406|
Global Fraction of Cell Lines Where Essential: 0/726
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/25|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/15|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/14|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/7|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 18306
* **Expression level (log2 read counts)**: 5.77
{{:chemogenomics:nalm6 dist.png?nolink |}}